Physician profile
Benjamin Watkins
NPI 1033384805
$7,132.92
in general payments reported to CMS, 2019-2025
22 companies · $3,628 in 2025
The $3,628 reported for 2025 was more than what 77% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,193 · 2023: $178 · 2024: $134 · 2025: $3,628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,800 · Food and Beverage: $1,140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,800.00 |
| Food and Beverage | $1,139.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $3,151.83 | 2019 | |
| Syndax Pharmaceuticals, INC. | $2,935.81 | 2025 | Revuforj |
| Genetix Biotherapeutics INC | $390.33 | 2023-2025 | Lyfgenia |
| Sanofi-Aventis U.S. LLC | $121.82 | 2025 | |
| Mesoblast, INC. | $119.90 | 2025 | Ryoncil |
| Novo Nordisk INC | $58.98 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $50.38 | 2023 | |
| Davol INC. | $41.30 | 2019 | |
| Springworks Therapeutics, INC. | $33.00 | 2025 | Gomekli |
| Y-Mabs Therapeutics, INC. | $31.34 | 2023 | Danyelza |
| Vertex Pharmaceuticals Incorporated | $29.72 | 2023 | |
| Csl Behring | $25.68 | 2023 | Hemgenix |
| Medunik USA INC. | $25.19 | 2025 | Siklos |
| Btg International INC. | $21.54 | 2025 | Voraxaze |
| Servier Pharmaceuticals LLC | $21.35 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $20.94 | 2024 | |
| Genentech USA, INC. | $20.56 | 2024 | Hemlibra |
| Adaptive Biotechnologies Corporation | $18.28 | 2024 | Clonoseq |
| Uswm, LLC | $14.97 | 2025 | Iwilfin |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Watkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.